(Total Views: 506)
Posted On: 11/03/2021 8:34:54 AM
Post# of 154140
From Seeking Alpha: CytoDyn (OTCQB:CYDY) posts preliminary results from the first five patients treated with leronlimab in its Phase 2 trial for NASH (nonalcoholic steatohepatitis) open label.
The Phase 2 trial for 90 patients is designed to test whether leronlimab may inhibit the devastating liver fibrosis associated with NASH.
Preliminary findings from five patients treated with leronlimab suggested fatty deposits were lowered on all 5 patients by as much as 45%, as compared to the baseline measurement.
In addition, fibrosis was also lowered by as much as 10%, in 4 out of 5 patients as compared to the baseline measurement (one patient exhibited no change in fibrosis).
NASH is a chronic liver disease characterized histologically by the presence of hepatic inflammation and cell injury due to hepatic fat accumulation equal or superior to 5 percent of hepatocytes.
Read Now: CytoDyn treats first patient in late-stage leronlimab Brazil COVID-19 trial
https://seekingalpha.com/news/3763649-cytodyn...News+Smart
The Phase 2 trial for 90 patients is designed to test whether leronlimab may inhibit the devastating liver fibrosis associated with NASH.
Preliminary findings from five patients treated with leronlimab suggested fatty deposits were lowered on all 5 patients by as much as 45%, as compared to the baseline measurement.
In addition, fibrosis was also lowered by as much as 10%, in 4 out of 5 patients as compared to the baseline measurement (one patient exhibited no change in fibrosis).
NASH is a chronic liver disease characterized histologically by the presence of hepatic inflammation and cell injury due to hepatic fat accumulation equal or superior to 5 percent of hepatocytes.
Read Now: CytoDyn treats first patient in late-stage leronlimab Brazil COVID-19 trial
https://seekingalpha.com/news/3763649-cytodyn...News+Smart
(1)
(0)
